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Abstract  
Acquired drug resistance in malignant tumors seriously hinders effective chemotherapy 
against cancer. The main mechanisms of drug resistance include decreased drug influx, 
increased drug efflux, as well as anti-apoptotic defense behavior in cancerous cells. To 
overcome these issues, we design a nanomedicine composed of pure doxorubicin 
(DOX) as the core and B-cell lymphoma-2 (Bcl-2) siRNA as the shell for synergistic 
cancer treatment. Between the core and shell, polyethylene glycol (PEG) and 
polyethylenimine (PEI) are employed to increase the stability of the core DOX NPs and 
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facilitate siRNA coating, respectively. In this design, the siRNA is able to inhibit the 
expression of Bcl-2 protein which has a role of protecting cancer cells from apoptosis. 
DOX is not only for anticancer therapy, but also acts as a nanocarrier for Bcl-2 siRNA 
delivery. Our studies show that Bcl-2 siRNA and DOX are efficiently delivered into 
tumor cells and tumor tissues, and such a co-delivery nanosystem possesses synergistic 
effects on tumor inhibition, enabling significantly enhanced anti-tumor outcome. This 
work demonstrates that the co-delivery of tumor suppressive Bcl-2 siRNA and 
chemotherapeutic agents without using an excipient material as a drug carrier represents 
a promising therapy for enhanced cancer therapy. 
Keywords: drug resistance; Bcl-2 siRNA; doxorubicin; co-delivery nanosystem; 
synergistic efficacy 
1. Introduction 
Multidrug resistance (MDR) of cancerous cells is one key factor that limits the 
effectiveness of current chemotherapy for tumor treatment.1,2 The main mechanisms of 
MDR include decreased drug influx, increased drug efflux, as well as anti-apoptotic 
defense behavior in cancerous cells.3,4 For example, B-cell lymphoma-2 (Bcl-2) is a 
well-known anti-apoptotic protein which situates at the outer mitochondrial membrane 
and can prevent apoptosis-inducing factor to enter cytoplasm and thereby inhibit cancer 
cell apoptosis.5,6 To avoid cancer cells being protected from apoptosis, it is apparent 
that Bcl-2 targeted siRNA can be employed to inhibit the expression of Bcl-2 protein.7,8 
However, there are many obstacles for efficient transport and transfection of siRNA 
such as intense negative charge, large molecular weight, and enzymatic degradation in 
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endosomes and lysosomes.9,10 To address these problems, various nanocarriers 
including polymeric, liposomal, and silica-based cationic nanoparticles (NPs) have 
been reported for siRNA delivery.11-13 However, these techniques possess a low drug 
loading capacity of generally below 30%.14-16 More importantly, these nanocarriers 
themselves do not play any therapeutic role and a large amount may be accumulated in 
patients over a long period of treatment, which will ultimately cause serious toxicity 
and inflammation.17-19  
For enhanced drug delivery systems, we design to employ pure anticancer drug 
molecules to synthesize NPs and then use them as a carrier to deliver siRNA gene for 
synergistic therapy. In this approach, the nanocarrier is made of pure drug molecules 
with a therapeutic role and will therefore alleviate the problem of introducing a large 
dose of excipient material during cancer treatment.20,21 In addition, combined therapy 
containing multiple antitumor agents is a highly effective strategy to treat cancers, 
especially those with acquired drug resistance.22-24 In such combinatorial treatment, 
simultaneous use of chemotherapeutic drug molecules and genetic components is 
particularly efficient in improving anticancer effect compared with individual 
therapy.25,26 The main reasons are that chemotherapeutic drugs induce apoptotic cell 
death,27,28 and, in the meantime, genes and genetic elements can increase the sensitivity 
of cells to chemotherapeutic drugs.29,30 
With this strategy, we herein report a Bcl-2 siRNA capped doxorubicin NPs 
(DOX@siRNA core@shell NPs) to realize a combinatorial therapy for enhanced 
anticancer efficacy (Scheme 1). Apparently, beyond therapeutic function, DOX NPs 
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also play a role as a nanocarrier for siRNA delivery. In this work, we synthesized 
DOX@siRNA NPs and then systematically investigated the morphology, size, and 
biocompatibility of the nanomedicine as well as its in vitro intracellular delivery and in 
vivo therapeutic efficacy. 
 
Scheme 1. The construction of DOX@siRNA NPs. 
2. Results and discussion  
2.1. Preparation and characterization of DOX@siRNA NPs  
The preparation of DOX@siRNA NPs involves the following steps. First, 
hydrophobic DOX is prepared by removal of hydrochloric acid from as-purchased 
hydrophilic DOX under alkaline conditions. Second, DOX NPs are produced using a 
solvent exchange method (Figure 1a). The diameter of these NPs is about 52 nm and 
the zeta potential is -17.2±0.41 mV (Figure 1c and d), as determined by a Zetasizer 
Nano ZS (Malvern Instruments). To improve the bio-stability and long-circulating 
ability of DOX NPs in blood stream, amphiphilic C18PMH-PEG copolymer molecules 
are applied to modify the particles’ surface in the third step (Figure S1).31 With PEG 
coating, the size of the DOX-PEG NPs slightly increases to about 53 nm and the zeta 
potential remains negative charged (–14.2±1.19 mV, Figure 1c and d). Fourth, positive 
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charged PEI is adsorbed to the surface of PEG tailored NPs through electrostatic 
attraction (DOX-PEG-PEI NPs) and render the surface positive charge (+22.3±1.21 mV, 
Figure 1d). The size of the NPs further increases to about 55 nm (Figure 1c). Finally, 
negatively charged Bcl-2 siRNA is attached to the PEI modified surface again through 
electrostatic attraction to form the outmost shell of the NPs (DOX@siRNA NPs, Figure 
1b). 
 
Figure 1. Characteristics of DOX@siRNA NPs. Scanning electron microscopy (SEM) 
images of (a) DOX NPs and (b) DOX@siRNA NPs (FEI Quanta 200). (c) Size and (d) 
Zeta potentials of DOX NPs, DOX-PEG NPs, DOX-PEG-PEI NPs and DOX@siRNA 
NPs. (e) Electrophoretic mobility of siRNA loaded DOX@siRNA NPs at different N/P 
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ratios. (f) Seven days stability studies of samples in PBS. 
To explore the condition under which siRNA molecules are firmly loaded onto the 
surface of PEI modified NPs, various N/P ratios (0.5, 1, 2.5, 5, and 10) between the 
combination of PEI modified NPs and Bcl-2 siRNA were tested and the influence of 
the ratio on the mobility of siRNA was investigated by gel retardation assay using pure 
siRNA as a control. If siRNA molecules tightly bind to NPs, they will not move in the 
gel. As displayed in Figure 1e, strong binding of siRNA on NPs can be achieved when 
the N/P ratio is 5/1 or greater. This is indicated by the fact that siRNA does not move 
in the gel at this ratio. Therefore, in this work, DOX@siRNA NPs were produced at 
N/P ratio of 5/1. At this ratio, with the loading of siRNA, the zeta potential of the NPs 
decreases to 10.2±0.89 mV. The drug payload of DOX@siRNA NPs could reach as 
high as 87.18%, which is significantly higher than carriers-based nanomedicines. 
The stability of DOX NPs, DOX-PEI NPs, DOX-PEG-PEI NPs, and 
DOX@siRNA NPs was investigated by measuring their sizes in PBS over a period of 
7 days. As shown in Figure 1f, DOX NPs and DOX-PEI NPs without surface 
PEGylation experience a rapid size growth and quickly form large agglomerations in 
PBS. In contrast, DOX-PEG-PEI NPs exhibit a high stability in PBS over the 7 days 
observation period, demonstrating the necessity of NPs surface modification with 
C18PMH-PEG polymer. After loading of siRNA on the surface, the obtained 
DOX@siRNA NPs can also maintain stable size with negligible size increase, making 
it possible for drug delivery in biological environment. 
2.2. In vitro release activity of DOX@siRNA NPs 
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 Figure 2. The release profiles of DOX@siRNA NPs. The release amount of (a) DOX 
and (b) siRNA at different pH values of 7.4, 5.8, and 4.3. 
In order to study the release of DOX and siRNA, DOX@siRNA NPs were placed 
in three buffer solutions with different pH values including 7.4, 5.8, and 4.3 for a 
duration of 72 hours. These three pH values were selected to simulate the acidity and 
alkalinity of bloodstream transportation (pH 7.4) and lysosome (pH between 4.3 and 
5.8). The release of DOX and fluorescein-labeled siRNA (FAM-siRNA) was collected 
through dialysis and the amount was monitored by measuring their fluorescence. It can 
be seen that in Figure 2a, at pH 7.4, 20.64% and 31.73% of DOX is released from 
DOX@siRNA NPs at 24 and 72 h, respectively. In comparison, the increase of acidity 
can significantly improve the release rate of DOX. At pH 5.8, 30.94% and 58.04% of 
DOX is liberated from NPs at 24 and 72 h, respectively. The release becomes more 
drastic at pH 4.3 at which 39.33% and 72.43% of DOX liberates from NPs at 24 and 
72 h, respectively. Similar results are also shown for the release profiles of siRNA at 
different pH values (Figure 2b). These phenomena indicate that DOX@siRNA NPs 
can release the incorporated drugs more rapidly in the acidic tumor environment, 
Page 7 of 33
ACS Paragon Plus Environment
ACS Applied Bio Materials
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
thereby enhancing their anticancer efficacy. 
2.3. In vitro therapeutic activity of DOX@siRNA NPs  
 
Figure 3. In vitro cytotoxicities of DOX@siRNA NPs against normal cancerous cells. 
Cell viabilities of 4T1 cells (a, b) and HeLa cells (c, d) when incubated with (1) 
DOX•HCl, (2) Lipo-siRNA, (3) DOX•HCl plus Lipo-siRNA, (4) DOX NPs, (5) DOX 
NPs plus Lipo-siRNA, and (6) DOX@siRNA NPs for 48 and 72 h. The highest 
concentrations, c, respectively represented (1) 20 μg/mL DOX, (2) 50 nM siRNA, (3) 
10 μg/mL DOX /25 nM siRNA, (4) 20 μg/mL DOX, (5) 10 μg/mL DOX/25 nM siRNA, 
and (6) 10 μg/mL DOX/25 nM siRNA. 
Our characterizations show that DOX@siRNA NPs have high stability, preferred 
release profiles for anticancer therapy, and desirable size for drug delivery. To assess 
their therapeutic efficacy, we firstly investigated the anti-proliferative effect using a 
Page 8 of 33
ACS Paragon Plus Environment
ACS Applied Bio Materials
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
MTT assay against 4T1 cancer cells and HeLa cancer cells. For proving DOX@siRNA 
NPs’ synergistic effect in anticancer treatment, the cytotoxicities of DOX•HCl, 
lipofectamine loaded Bcl-2 siRNA (Lipo-siRNA), DOX•HCl plus Lipo-siRNA, DOX 
NPs, and DOX NPs plus Lipo-siRNA (simple physical mixture of the two) were also 
measured for comparison. As indicated in Figure 3a, with the highest concentration 
and at 48 hours after drug application, DOX•HCl plus Lipo-siRNA (10.02% viability) 
exhibit a slightly higher anti-proliferative effect in comparison with individual 
DOX•HCl (13.66% viability) and Lipo-siRNA (69.72% viability). Moreover, DOX 
NPs plus Lipo-siRNA (35.99% viability) exhibited a higher anti-proliferative effect in 
comparison with DOX NPs (47.68% viability) and Lipo-siRNA (69.72% viability). 
These results indicate that the combination of DOX and Bcl-2 siRNA possesses 
synergetic effect. Attractively, DOX@siRNA NPs display a significantly higher anti-
proliferative effect (13.66% viability) than the simple physical mixture of DOX NPs 
and Lipo-siRNA group (40.90% viability). This may be due to the fact that 
DOX@siRNA NPs aid the delivery of siRNA, enabling the simultaneous transport of 
both therapeutics to the treated cells. By 72 h after incubation (Figure 3b), 
DOX@siRNA NPs possess a moderately increased efficacy of 10.61% viability, 
demonstrating the effectiveness in killing cancer cells. Furthermore, the combination 
index (CI) analysis was calculated by evaluating the anticancer efficacy of DOX NPs, 
Lipo-siRNA and DOX@siRNA NPs against HeLa cells. The CI values of below 1 
represents synergism. In our experiments, all CI values of DOX@siRNA NPs are 
obviously below 1, indicating the synergistic antitumor effect of DOX and Bcl-2 siRNA 
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in our DOX@siRNA NPs design. Similar results are observed in the case of treating 
HeLa cells with these drugs as shown in Figure 3c and d. These anti-proliferative effect 
assays prove an excellent potential of utilizing DOX@siRNA NPs for efficient 
synergistic therapy. 
 
Figure 4. In vitro cytotoxicities of DOX@siRNA NPs against drug resistant cancer 
cells. Cell viabilities of (a, b) MCF-7 cells and (c, d) MCF-7/ADR cells when incubated 
with (1) DOX•HCl, (2) Lipo-siRNA, (3) DOX•HCl plus Lipo-siRNA, (4) DOX NPs, 
(5) DOX NPs plus Lipo-siRNA, and (6) DOX@siRNA NPs for 48 and 72 h, 
respectively. The concentrations were as the same as the above MTT experiments. 
Following the confirmation that DOX@siRNA NPs can effectively kill normal 
cancer cells, we next studied whether the material is able to overcome drug resistant 
ones. For this purpose, we treated MCF-7/ADR cells, a DOX resistant derivatives of 
MCF-7 cells which overexpressing Bcl-2, with our DOX@siRNA NPs. DOX•HCl, 
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Lipo-siRNA, DOX•HCl plus Lipo-siRNA, DOX NPs and DOX NPs plus Lipo-siRNA 
were set as control groups. The results are presented in Figure 4. Firstly, although 
DOX•HCl show potent efficacy in killing normal MCF-7 cells (13.80% viability at the 
highest drug concentration after 72 h incubation), the function is much less effective 
for MCF-7/ADR cells (49.54% viability under the same condition). The reduction of 
efficacy is even more obvious with shorter period of incubation such as 48 h. For 
example, the viability of MCF-7/ADR cells remains above 60% at 20 μg/mL DOX•HCl 
after 48 h. Similar phenomenon also occurs on DOX NPs. Again, at the highest 
concentration, the viabilities of MCF-7 cells and MCF-7/ADR cells are 18.56% and 
44.52%, respectively, after incubation with DOX NPs for 72 h. The over expression of 
Bcl-2 on MCF-7/ADR cells might be an important reason for drug resistance.32,33 The 
combinatorial therapy of physical mixture of DOX and Bcl-2 siRNA (DOX•HCl plus 
Lipo-siRNA, DOX NPs plus Lipo-siRNA) can alleviate the drug resistance of cancer 
cells.34,35 This is reflected from the result of low viability of drug resistant cells when 
incubated with DOX•HCl plus Lipo-siRNA (28.55%), and DOX NPs plus Lipo-siRNA 
(28.78%) after 72 h incubation. These values are dramatically lower than the viabilities 
of 49.54% and 44.52% for the groups of DOX•HCl and DOX NPs, respectively. 
Moreover, DOX@siRNA NPs can further enhance the efficacy against drug resistant 
cancer cells to the viability of 23.06%, revealing a greaet potential with respect to MDR 
reversal in chemotherapy. 
2.4. Intracellular uptake of DOX@siRNA NPs 
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 Figure 5. Cellular internalization of DOX@siRNA NPs in cancer cells. Subcellular 
localization of (a) DOX•HCl, (b) DOX NPs, (c) DOX@siRNA NPs in MCF-7 and 
MCF-7/DOX ADR cells after 4 h incubation. Blue and red indicates cell nuclei staining 
and DOX fluorescence, respectively. The flow cytometry analysis of the cellular 
internalization quantities of different drugs by (d) MCF-7 and (e) MCF-7/DOX ADR 
cells. Scale bar represents 20 µm. 
Since DOX@siRNA NPs present a strong efficacy in killing both normal and drug 
resistant cancer cells, we next surveyed the cellular internalization ability of this 
material to obtain a basic understanding of their potency. In the initial experiment, the 
intracellular uptake of siRNA, DOX, and DOX@siRNA NPs by HeLa cells was studied 
by confocal microscopy as a test case. DOX has a red fluorescence, while siRNA was 
labeled with 6-carboxyfluorescein (FAM, green fluorescence) and nucleus was stained 
with 4′,6-diamidino-2-phenylindole (DAPI, blue fluorescence). DOX NPs and 
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lipofectamine 2000 carrying FAM-siRNA were used as two controls. As shown in 
Figure S3, after 4 h incubation, red fluorescence can be observed in the DOX NPs 
treated cells, and green fluorescence is detected in the lipo-siRNA treated cells. In the 
DOX@siRNA NPs group, both red fluorescence from DOX and green from FAM-
labeled siRNA are able to be observed in cells, validating the contemporary cellular 
internalization of anticancer drugs and genes. This result demonstrates that 
simultaneous delivery of DOX and siRNA to cancer cells can be realized with our 
strategy, leading to the feasibility of producing cooperative effects. 
After observing intracellular delivery of DOX@siRNA NPs in normal cancer cells, 
we also assessed their internalization in drug resistant ones. In the investigation, MCF-
7 and MCF-7/ADR cells were incubated with DOX@siRNA NPs followed by confocal 
microscopy imaging (Figure 5a-c). DOX•HCl and DOX NPs were also studied for 
comparison. From these images, it can be seen that DOX•HCl can efficiently enter 
MCF-7 cells, but in a sharp contrast, the internalization of these molecules to MCF-
7/ADR cells significantly drops. However, DOX@siRNA NPs treated MCF-7/ADR 
cells still display very strong red fluorescence. These findings are further supported by 
quantity analysis of the intracellular uptake by flow cytometry. Figure 5d indicates that 
DOX•HCl possess the highest intracellular uptake among the three groups when 
incubated with MCF-7 cells, but their internalization in MCF-7/ADR cells becomes the 
lowest. This observation can partially explain why DOX•HCl has very low efficacy in 
killing MCF-7/ADR cells although it works very well toward normal MCF-7 cells. In 
comparison, DOX@siRNA NPs incubated MCF-7/ADR cells present stronger 
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fluorescence than DOX•HCl and DOX NPs groups (Figure 5e). The mean values of 
DOX fluorescence within MCF-7/DOX ADR cells treated with DOX•HCl, DOX NPs 
and DOX@siRNA NPs are 29.49, 49.68 and 76.92, respectively (Table S1). The data 
are consistent with the observation from the confocal microscopy images, 
demonstrating that the DOX NPs coordinated with Bcl-2 siRNA can improve the 
therapeutics concentration in drug resistant cells. This is one of the reasons that 
DOX@siRNA NPs show the highest efficacy in killing MCF-7/ADR cells (Figure 4). 
2.5. In vivo antitumor activity 
We next explored their effectiveness in in vivo therapy. For this purpose, we firstly 
studied their pharmacokinetics in mouse model. BALB/c mice were treated with 
DOX@siRNA NPs, followed by analysis of the fluorescence of DOX in blood samples 
collected at different time points after injection. As shown in Figure S4, a long blood 
circulation half-life of 3.5 h is observed for DOX@siRNA NPs, whereas the circulation 
time of DOX•HCl is less than half of an hour. The prolonged circulation will increase 
drug delivery to tumors via enhanced permeability and retention (EPR) effect for high 
therapeutic efficacy. 
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 Figure 6. In vivo activities of DOX@siRNA NPs. (a) Biodistribution and (b) in vivo 
fluorescence image of DOX@siRNA NPs. (c) Evolution of the tumor volume after 
intravenous injection of (1) saline, (2) DOX•HCl, (3) Lipo-siRNA, (4) DOX•HCl plus 
Lipo-siRNA, (5) DOX NPs, (6) DOX NPs plus Lipo-siRNA, and (7) DOX@siRNA 
NPs. The formulation concentration was (2) 1 mg/kg DOX, (3) 10 μg siRNA, (4) 0.5 
mg/kg DOX/5 μg siRNA, (5) 1 mg/kg DOX, (6) 0.5 mg/kg DOX/5 μg siRNA, and (7) 
0.5 mg/kg DOX/5 μg siRNA. (d) Change of the body weight of 4T1 tumor bearing mice 
over time. 
Following the half-life investigation of DOX@siRNA NPs, their biodistribution 
in major organs and tumors were detected by determining the fluorescence of DOX in 
tumor-bearing BALB/c mice. The fluorescence intensity of DOX in each organ was 
calculated by deducting the autofluorescence of untreated mice. Figure 6a shows that 
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30.50% of the administered NPs does appears in liver, and 21.34% in tumor at 2 h after 
NP administration. Other NPs mainly distribute in kidney (14.93%), intestine (11.70%) 
and skin (7.39%). Attractively, it is noted that the fluorescence intensity of tumor 
enhances with time. At 12 h post injection, 26.12% and 39.28% of the NPs are in liver 
and tumor tissue, respectively. At 48 h, the fluorescence intensity in tumor continues to 
increase, indicating 44.08% of NPs in the tumor tissue, which is more than that in the 
major organs. The high delivery amount of DOX@siRNA NPs can be attributed to the 
prolonged blood circulation time and the surface modification of NPs by PEG, which 
reduces the capture of NPs by the reticulo-endothelial (RES) system and 
correspondingly boosts drug accumulation in tumor. 
To visibly observe the accumulation of nanomedicine in tumor, DOX@siRNA 
NPs were intravenously administered into BALB/c mice planted with 4T1 tumor 
followed by fluorescence imaging. It can be seen in Figure 6b that DOX@siRNA NPs 
treated mouse exhibits obvious red fluorescence in the tumor site at 6 h after injection. 
This result demonstrates the good potential of using these DOX@siRNA NPs for tumor 
imaging. 
After we demonstrate that DOX@siRNA NPs have long half-life in blood 
circulation and can efficiently transport to tumor, the key issue will be whether this 
nanomedicine is able to effectively inhibit tumor growth with a low side effect. In the 
study, mice bearing 4T1 tumor were selected as animal models. When the tumor’s sizes 
increased to 50-100 mm3, the mice were randomly divided into several groups for 
testing the therapeutic function of DOX•HCl, Lipo-siRNA, DOX•HCl plus Lipo-
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siRNA, DOX NPs, DOX NPs plus Lipo-siRNA, and DOX@siRNA NPs. The injection 
of drugs was administered twice on Day 0 and 7. Mice with injection of saline were 
applied as a negative control group.  
During the therapy, the tumor volume and body weight of each mouse were 
monitored daily for 14 days. As displayed in Figure 6c and Figure S5, the tumor 
volume of saline treated group rapidly increases to 7.56±0.72 fold of the original value 
by the 14th day. The treatment of tumor by DOX•HCl and Lipo-siRNA can moderately 
slow down the tumor growth. Within the same time window, the tumor grows to 
5.59±0.68 and 5.14±0.63 fold of the initial volume for DOX•HCl and Lipo-siRNA 
treated groups, respectively. Once DOX is made into the form of nanomedicine, the 
tumor inhibition efficacy dramatically improves. This is indicated by the much slower 
tumor growth to 2.54±0.45 fold of the starting volume. This can be partly ascribed to 
the extended blood circulation time of DOX NPs and the EPR effect of nanomedicine 
during in vivo application.36,37 Similar to the findings from the in vitro test of cell anti-
proliferative effect, the physical mixture of DOX NPs plus Lipo-siRNA can actually 
work substantially better than individual DOX NPs and Lipo-siRNA, which is proved 
by the tumor growth of only 1.95±0.33 fold. Most importantly, DOX@siRNA NPs 
group reveals the highest tumor inhibition ability (1.79±0.39 fold tumor growth) among 
all groups, thus confirming the in vivo synergistic therapeutic effect of DOX and Bcl-2 
siRNA. We further carried out hematoxylin-eosin (H&E) and terminal 
deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) assay 
staining of the tumor tissue of the treated mice. Compared with individual drugs, 
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DOX@siRNA NPs lead to obvious cell destruction, including lower nuclear-to-
cytoplasmic ratio (H&E stain) and larger number of TUNEL-positive cells (Figure S6), 
providing a potentially synergistic antitumor efficacy for cancer therapy.  
Although the tumor grow inhibition is just moderately better than the physical 
mixture of DOX-PEG NPs and Bcl-2 siRNA, we foresee that the tight binding of siRNA 
to the DOX NP surface will lead to less side effect. The reason is that siRNA can be 
better delivered to tumor together with DOX-PEG NPs. It can also avoid the possible 
widespread delivery of siRNA to healthy organs and tissues in its free molecule 
state.38,39 To preliminarily investigate the safety performance of DOX@siRNA NPs, the 
body weights of all the above groups of mice were measured in Figure 6d. It is evident 
that the body weights of the mice treated with saline sharply drop after Day 8, which 
might be on accounts of excessive tumor growth. In comparison, the DOX@siRNA 
NPs treated mice do not show any sign of body weight reduction. These results prove 
that DOX@siRNA NPs at the used dose probably possess very low in vivo toxicity. 
Furthermore, the H&E staining of the major organs (heart, liver, spleen, lung, and 
kidney) of DOX@siRNA NPs treated mice (Figure S7) indicates that there are no 
noticeable organ damage and inflammatory lesion. 
Bcl-2 siRNA has been tested in clinical trials; however, the anticancer effect of 
siRNAs is limited by many barriers, such as rapid degradation, less cellular uptake and 
poor tumor accumulation.40,41 In this work, DOX@siRNA NPs possess enhanced 
stability in the physiological environment and prolonged blood circulation time (3.5 h) 
than Lipo-Bcl-2 siRNA, which is in use for clinical applications. Additionally, several 
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nanocarriers-based systems were previously reported for co-delivery of doxorubicin 
and Bcl-2 siRNA, but their drug loading capacity (DLC) is always low, such as glycol 
chitosan-based nanoparticles, cationic star-block terpolymer, mesoporous silica 
nanoparticles with DLC of approximately 10%, 20%, and 40%, respectively.42,43,44 In 
significant contrast, the DLC of our DOX@siRNA NPs is as high as 87.18%, which is 
a step improvement. Beyond the high DLC, siRNA is plays a therapeutic role in the 
system, which means that the overall therapeutic component is even higher and we use 
negligible excipients. Overall, we designed an effective and safe strategy to deliver 
DOX and Bcl-2 siRNA for cancer therapy. 
3. Conclusions 
In conclusion, we put forward a novel strategy of using pure drug molecules to 
make nanoparticles for delivering siRNA and realizing synergistic anticancer therapy. 
As a test case, we synthesized DOX@siRNA NPs that are spherical and possess a 
diameter of about 55 nm. These NPs have significantly extended blood circulation half-
life and can effectively enter DOX resistant MCF-7 cancer cells. In line with these 
characteristics, DOX@siRNA NPs result in stronger anti-proliferative effect than 
DOX•HCl, Lipo-siRNA and DOX NPs in drug resistant cancer cells, exhibiting 
synergistic anticancer efficacy. Most notably, DOX@siRNA NPs considerably inhibit 
tumor growth and exhibit very low toxicity. Overall, our method is able to achieve 
potent anticancer efficacy in tumor treatment and overcome drug resistance. We expect 
that this approach possesses significant potential for clinic applications. 
4. Experiments 
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4.1. Preparation of DOX@siRNA NPs 
To achieve DOX NPs, the hydrophilic DOX•HCl (99%, Beijing ZhongShuo 
Pharmaceutical Technology Development Co., Ltd.) was first converted to hydrophobic 
DOX, followed by addition of TEA at room temperature. The volume ratio of 
DOX•HCl/DMSO solution (1 mg/mL) to TEA is 10:1. Subsequently, 200 µL 
DOX/DMSO solution was dropwisely added into 10 mL water with active stirring, 
which generated DOX NPs in aqueous solution. C18PMH-PEG was prepared 
according to the previous report. In brief, 10 mg (1 eq) of C18PMH (Sigma, St. Louis, 
MO) and 143 mg (1 eq) of mPEG-NH2 were dissolved in 5 mL of DCM reagent with 
the addition of 6mL of TEA and 11 mg of EDC. The reaction solution was under stirring 
for 24 h and then the DCM solvent was dried by nitrogen flow. The remained solid 
product was dissolved in water followed by 2 days of dialysis in water in a dialysis bag 
with an MWCO of 14 kDa to remove unreacted mPEG-NH2. After lyophilization, the 
end product is a white solid which can be stored at 4℃. To modify the surface of as-
prepared DOX NPs, 400 µL of 0.5 mg/mL C18PMH-PEG aqueous solution were added 
to 10 mL of DOX NPs solution followed by ultrasonic treatment of 5 min and room 
temperature incubation of 1 h. After this step, the DOX-PEG NPs were dropwisely 
added into PEI solution (1 mg/mL) and left for overnight to obtain DOX-PEG-PEI NPs. 
For siRNA loading, DOX-PEG-PEI NPs were diluted to different concentrations and 
added to the siRNA solution (20 mM) to obtain different N/P ratios in Mili-Q 
water/medium (Invitrogen, Carlsbad, USA). The tested N/P ratios include 0.5, 1, 2.5, 5, 
and 10. The drug loading efficiency of DOX was measured using HPLC (Agilent 1200). 
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Besides, the N/P ratio was calculated by the molar ratio of PEI nitrogen to RNA 
phosphate. 
4.2.In vitro release profiles 
The concentration of DOX@siRNA NPs was 0.5 μg/mL. In this experiment, 
siRNA was marked with fluorescein-labeled siRNA (FAM-siRNA, green fluorescence, 
Genpharm, Shanghai, China). DOX@siRNA NPs were placed into the release buffer, 
followed by immediate transformation to individual dialysis tubes with an MWCO of 
14 kDa followed by immersion into 50 mL of buffers of different pH at 37 ℃. At 
different times, 2 mL of the buffer were removed from each group for fluorescence 
measurement and the same amount of fresh buffer was added. The released DOX and 
FAM-siRNA were determined by the fluorescence intensity. The released DOX and 
FAM-siRNA were quantified by measuring the fluorescence intensity. (DOX Ex/Em: 
490/596 nm; FAM Ex/Em: 490/515 nm). These experiments were carried out in 
triplicate and the average values are shown. 
4.3.Cell culture 
A human cervical cell line (HeLa cells), murine 4T1 breast cancer cell line (4T1 
cells), human breast adenocarcinoma cell line (MCF-7 cells) and DOX resistant 
derivatives of MCF-7 cells overexpressing Bcl-2 (MCF-7/ADR cells) were from 
American Type Culture Collection (ATCC, Manassas, VA, USA).  
4.4.Intracellular uptake of DOX@siRNA NPs 
HeLa cells were seeded on coverslips and left for 24 h. Subsequently, 
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DOX@siRNA NPs were added and incubated with the cells for 3 h. Before observation 
with confocal microscopy, the culture medium was removed and the cells were washed 
twice with cold PBS (pH 7.4, 0.01M) and fixed with 4% formaldehyde (Sigma-Aldrich, 
St. Louis, USA). Finally, the cells were studied using a Leica laser scanning confocal 
microscope. 
4.5.In vitro anti-proliferative effect 
One hundred µL of complete media with HeLa, MCF-7/ADR, MCF-7, and 4T1 
cells were seeded in 96-well plates (~6,000 cells/well) and incubated for 24 h. 
Subsequently, 25 µL of samples were placed to each well for incubation with the cells 
(37 ℃, 5% CO2). After the cells were further incubated for 48 and 72 h, the cell 
viabilities were quantified with a standard MTT assay. CI is defined as: CI = D1/Dm1 + 
D2/Dm2, D1 and D2 represent the concentrations of drug 1 and drug 2, respectively, that 
are combined to achieve a certain cytotoxicity, while Dm1 and Dm2 are the 
concentrations of the two individual drugs to generate the same antitumor effect. 
4.6.Intracellular uptake by MCF-7 and DOX resistant MCF-7 cells 
Normal MCF-7 cells and MCF-7/ADR cells were separately seeded into 24-well 
plates at a density of 5×104/well in DMEM medium containing 10% FBS for 18 h. The 
medium was then replaced by 1 mL of DMEM (serum free), DOX•HCl, DOX NPs, and 
DOX@siRNA NPs and incubated for 4 h with a DOX concentration of 20 μg/mL. After 
the incubation, the medium was removed and the cells were washed three times in PBS. 
The supernatant of centrifuge product was removed and the precipitate cells were 
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washed three times with PBS. Finally, the internalization of DOX in cells was observed 
by confocal microscopy. In addition to the confocal microscopy study, another batch of 
cells with the same treatment was washed, trypsinized, and collected for flow 
cytometric analysis. 
4.7.Measurement of blood circulation half-life 
All experiments involving animals were performed in accordance with the 
guidelines of the Institutional Animal Care and Use Committee. BALB/c mice were 
administered through intravenous injection of 200 µL of DOX@siRNA NPs and 
DOX∙HCl containing the same DOX concentration of 1 mg/mL. At each time point, 
blood samples were collected and solubilized in lysis buffer for fluorescence intensity 
measurement.  
4.10. Biodistribution 
4T1 bearing BALB/c mice were treated with 200 µL of 1 mg/ml of DOX@siRNA 
NPs, followed by sacrifice at different time points. The fluorescence intensities of 
organs and tissues were measured. The tissue autofluorescence was subtracted to 
calculate the amount of DOX. 
4.11. In vivo imaging 
The hair of 4T1 tumor-bearing mice was removed followed by intravenous 
injection of 200 µL of DOX@siRNA NPs (DOX concentration was 1 mg/mL). An 
untreated mouse was used as a control. The DOX@siRNA NPs treated mice were 
imaged with a Maestro in vivo fluorescence imaging system (CRi Inc.) at 6 h post 
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injection. 
4.12. In vivo antitumor activity  
The mice were randomly split to 7 groups after the sizes of tumors were in the 
range of about 55-95 mm3. Samples was injected into each group of mice via the tail 
vein. The treatment was repeated on day 7. The tumor size and body weight of each 
mouse were measured and recorded every day for an overall period of two weeks. 
4.13. Tissue section analysis 
4T1 tumor-bearing mice were euthanized at 14 days post administration with 
DOX@siRNA NPs. Subsequently, the organs (heart, liver, spleen, lung, and kidney) 
and tumors were dissected and fixed with 10% neutral buffered formalin and then 
embedded in paraffin. Afterwards, paraffin was sectioned into slices with a thickness 
of 4 μm for H&E staining and TUNEL assay. The mouse injected with saline was used 
as a control group. 
Associated Content 
Supporting Information 
SEM images of DOX-PEG NPs and DOX-PEG-PEI NPs during the layer-by-layer self-
assembly process. Combination index of DOX@siRNA NPs. Subcellular localization 
of DOX·HCl, DOX NPs and DOX@siRNA NPs in Hela cells after 4 h incubation. 
DOX fluorescence values measured in MCF-7 cells and MCF-7/DOX ADR cells with 
DOX·HCl, DOX NPs and DOX@siRNA NPs estimated by flow cytometry. The 
concentration of DOX·HCl and DOX@siRNA NPs in blood at different time points 
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after injection. The digital pictures of the tumors of mice before (Day 0) and after (Day 
14) intravenous injection of different materials. Histological photomicrographs of H&E 
and TUNEL staining of the tumor sections of different groups with various treatments. 
H&E staining of the major organs (heart, liver, spleen, lung, and kidney) of 
DOX@siRNA NPs and saline treated mice. 
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Figure S1. SEM images of DOX-PEG NPs and DOX-PEG-PEI NPs during the 
layer-by-layer self-assembly process. 
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Figure S2. Combination index of DOX@siRNA NPs against HeLa cells. 
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Figure S3. Subcellular localization of DOX·HCl, DOX NPs and DOX@siRNA NPs 
in Hela cells after 4 h incubation. Blue represents the fluorescence of DAPI for cell 
nuclei staining, red indicates the fluorescence of DOX for monitoring drug delivery, 
green indicates the fluorescence of fluorescein-labeled siRNA (FAM-siRNA). 
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Table S1. DOX fluorescence values measured in MCF-7 cells and MCF-7/DOX ADR 
cells with DOX·HCl, DOX NPs and DOX@siRNA NPs estimated by flow cytometry. 
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Figure S4. The concentration of DOX·HCl and DOX@siRNA NPs in blood at 
different time points after injection. The unit was the percentage of injected dose per 
gram tissue (% ID g-1).  
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Figure S5. The cameral images of mice tumors after intravenous injection of different 
groups at Day 14, the cameral image of Day 0 was set as control. 
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Figure S6. Histological photomicrographs of H&E and TUNEL staining of the tumor 
sections of different groups with various treatments, including (1) saline, (2) 
DOX•HCl, (3) Lipo-siRNA, (4) DOX•HCl plus Lipo-siRNA, (5) DOX NPs, (6) DOX 
NPs plus Lipo-siRNA, and (7) DOX@siRNA NPs. The formulation contained (2) 1 
mg/kg DOX, (3) 10 μg siRNA, (4) 0.5 mg/kg DOX/5 μg siRNA, (5) 1 mg/kg DOX, 
(6) 0.5 mg/kg DOX/5 μg siRNA, and (7) 0.5 mg/kg DOX/5 μg siRNA. 
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Figure S7. H&E staining of the major organs (heart, liver, spleen, lung, and kidney) 
of DOX@siRNA NPs and saline treated mice (organs collected at 14 days after initial 
treatment) (100× magnification). 
